单核细胞趋化蛋白-1水平与动静脉内瘘血管成形术后再狭窄
前瞻性纳入59例功能障碍动静脉内瘘行经皮腔内血管成形术患者,术后2天和2周单核细胞趋化蛋白-1显著升高;再狭窄组术后2天单核细胞趋化蛋白-1百分比变化高于通畅组,且术后2天单核细胞趋化蛋白-1升高是再狭窄的独立预测因子,>25%升高与再狭窄显著相关(HR 5.36)。
要点
- 动静脉内瘘血管成形术后2天和2周循环单核细胞趋化蛋白-1显著升高。
- 再狭窄组术后2天单核细胞趋化蛋白-1百分比变化中位数47%高于通畅组17%。
- 术后2天单核细胞趋化蛋白-1升高>25%与再狭窄显著相关(HR 5.36)。
核心结论
- 循环单核细胞趋化蛋白-1水平在经皮腔内血管成形术后2天和2周升高;术后早期单核细胞趋化蛋白-1升高与动静脉内瘘再狭窄相关。
研究设计与样本
- 前瞻性研究,2010年1月至2012年7月纳入59例因功能障碍动静脉内瘘转诊行经皮腔内血管成形术的患者,其中3例因手术失败或急性感染被排除。
- 另纳入17例无显著狭窄的患者作为对照组。
- 在基线、术后2天、2周和3个月从动静脉内瘘采血,临床随访每月一次持续3个月,3个月末安排血管造影随访。
主要发现
- 56例患者完成临床随访,23例(41%)出现症状性再狭窄。
- 经皮腔内血管成形术后2天和2周单核细胞趋化蛋白-1显著升高(均P<0.001)。
- 再狭窄组术后2天单核细胞趋化蛋白-1百分比变化中位数47%(四分位距27%-65%)高于通畅组中位数17%(四分位距10%-25%),P<0.001。
- 52例患者完成血管造影随访,术后2天单核细胞趋化蛋白-1升高与相对管腔丢失呈正相关(r=0.53;P<0.001)。
- 多因素分析中,术后2天单核细胞趋化蛋白-1升高是再狭窄的独立预测因子;受试者工作特征分析显示术后单核细胞趋化蛋白-1升高>25%与经皮腔内血管成形术后再狭窄显著相关(风险比5.36;95%置信区间1.81至15.8)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Inflammation is relevant in restenosis of atherosclerotic vascular diseases, but its role in dialysis arteriovenous fistula remains unknown. In animal studies, upregulation of monocyte chemoattractant protein-1 has been shown in venous segments of arteriovenous fistula. We, therefore, aimed to investigate serial changes in circulating monocyte chemoattractant protein-1 after percutaneous transluminal angioplasty of dialysis arteriovenous fistulas and its relation to restenosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fifty-nine patients with dysfunctional arteriovenous fistulas that were referred for percutaneous transluminal angioplasty were enrolled prospectively between January of 2010 and July of 2012. Three of them were excluded due to percutaneous transluminal angioplasty failure or acute infection. Blood was sampled from arteriovenous fistulas at baseline, 2 days, 2 weeks, and 3 months after percutaneous transluminal angioplasty. Clinical follow-up was continued monthly for 3 months. Angiographic follow-up was arranged at the end of 3 months. Seventeen patients without significant stenosis were enrolled as the control group. RESULTS: Fifty-six patients completed clinical follow-up. Significant increases in monocyte chemoattractant protein-1 were observed at 2 days and 2 weeks (both P<0.001) after percutaneous transluminal angioplasty. Twenty-three (41%) patients had symptomatic restenosis. The restenosis group had a higher percentage change in monocyte chemoattractant protein-1 levels at 2 days (median =47%; interquartile range, 27%-65% versus median =17%; interquartile range, 10%-25%; P<0.001) after percutaneous transluminal angioplasty compared with the patent group. Fifty-two patients completed angiographic follow-up. A positive correlation between relative luminal loss and monocyte chemoattractant protein-1 increase at 2 days after percutaneous transluminal angioplasty was found (r=0.53; P<0.001). In multivariate analysis, postangioplasty monocyte chemoattractant protein-1 increase at 2 days was an independent predictor of restenosis. Using receiver operator characteristic analysis, >25% postangioplasty increase of monocyte chemoattractant protein-1 was significantly associated with restenosis after percutaneous transluminal angioplasty (hazard ratio, 5.36; 95% confidence interval, 1.81 to 15.8). CONCLUSIONS: Circulating monocyte chemoattractant protein-1 levels were elevated 2 days and 2 weeks after percutaneous transluminal angioplasty. Early postangioplasty increase of monocyte chemoattractant protein-1 level was associated with restenosis of arteriovenous fistulas.
引用
- Wu CC, Chen TY, Hsieh MY, et al. Monocyte Chemoattractant Protein-1 Levels and Postangioplasty Restenosis of Arteriovenous Fistulas. Clin J Am Soc Nephrol. 2016. PMID: 27797894. doi:10.2215/CJN.04030416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。